NOVEL POLYMORPHIC CRYSTAL FORMS OF 5-(2-{[6-(2,2-DIFLUORO-2-PHENYLETHOXY)HEXYL]AMINO}-1-(R)-HYDROXYETHYL)-8-HYDROXYQUINOLIN-2(1H)-ONE, HEMINAPADISYLATE AS AGONIST OF THE beta2 ADRENERGIC RECEPTOR

NOVEL POLYMORPHIC CRYSTAL FORMS OF 5-(2-{[6-(2,2-DIFLUORO-2-PHENYLETHOXY)HEXYL]AMINO}-1-(R)-HYDROXYETHYL)-8-HYDROXYQUINOLIN-2(1H)-ONE, HEMINAPADISYLATE AS AGONIST OF THE beta2 ADRENERGIC RECEPTOR

The present invention is directed to novel polymorphic crystal forms of a 5-(2-{[6-(2,2-difluoro-2-phenylethoxy)hexyl]amino}-1-(R)-hydroxyethyl)-8-hydroxyquinolin-2(1H)-one, heminapadisylate. The invention is also directed to pharmaceutical compositions comprising said polymorphic crystal forms, met...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: CARRERA CARRERA, FRANCESC, BALAGUER ARDANUY, ELVIRA, MOYES VALLS, ENRIQUE, AMAT MESTRES, GEMMA, MARCUETA HEREU, IOLANDA
Format: Patent
Sprache:eng ; fre
Schlagworte:
CHEMISTRY
HETEROCYCLIC COMPOUNDS
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
ORGANIC CHEMISTRY
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online-Zugang:Volltext bestellen
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:The present invention is directed to novel polymorphic crystal forms of a 5-(2-{[6-(2,2-difluoro-2-phenylethoxy)hexyl]amino}-1-(R)-hydroxyethyl)-8-hydroxyquinolin-2(1H)-one, heminapadisylate. The invention is also directed to pharmaceutical compositions comprising said polymorphic crystal forms, methods of using them to treat respiratory diseases associated with beta2 adrenergic receptor activity and a process for preparing such polymophic crystal forms. La présente invention porte sur de nouvelles formes cristallines polymorphes d'un héminapadisylate de 5-(2-{[6-(2,2-difluoro-2-phényléthoxy)hexyl]amino}-1-(R)-hydroxyéthyl)-8-hydroxyquinoléin-2(1H)-one. L'invention porte également sur des compositions pharmaceutiques comprenant lesdites formes cristallines polymorphes, sur des procédés d'utilisation de celles-ci pour traiter des maladies respiratoires associées à l'activité des récepteurs adrénergiques beta2 et sur un procédé pour la préparation de telles formes cristallines polymorphes.